Hexaell Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese biotech creating off-the-shelf cell therapies for regenerative medicine applications.
Regenerative MedicineOncologyNeurology
Technology Platform
Gene-editing platform to engineer allogeneic stem and immune cells for enhanced therapeutic function and manufacturability.
Opportunities
Large addressable markets for degenerative diseases where current treatments are only palliative.
Risk Factors
Scientific risks associated with long-term safety and efficacy of engineered allogeneic cell products.
Competitive Landscape
Competes in the crowded but promising Chinese allogeneic cell therapy space, where differentiation through engineering is critical.